USPTO serial 79435367
MABQUEST THERAPEUTICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 19, 2026
- Examiner
- MCDORMAN, ROGER THOMAS
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with MABQUEST THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Andrea L. Hintz
Andrea L. Hintz Resonate IP, LLCP.O. Box 1650Bend, OR 97709United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical, biochemical, biological and biotechnological preparations for use in industry and science other than for medical or veterinary use; chemical, biological and biotechnological preparations, in particular polypeptides and proteins for development or manufacture of reagents for use in industry and science; biological preparations, in particular polypeptides or proteins for use in laboratories and for non-medical diagnosis and analysis in industry and science; chemical and biochemical substances being additives for use in the manufacture of pharmaceuticals; chemical and biochemical substances for use in the manufacture of pharmaceuticals for treating cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; stem cells for research purposes; stem cells for scientific use; cultures of microorganisms other than for medical and veterinary use; cell culture media for scientific and research purposes | ACTIVE | — |
| 005 | Pharmaceutical products for treatment of cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; medicinal preparations for disease treatment, namely, for preventing or treating cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; preparations for medical treatments, in particular preparations based on polypeptides and proteins for treatment of cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; protein complexes for diagnosing cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; synthetic peptides for pharmaceutical use, namely, for treatment of cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; diagnostic agents, preparations and substances for medical purposes; diagnostic substances for medical use; medicinal preparations and substances for preventing and treating cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; pharmaceutical preparations and substances for preventing and treating cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; agents and medicines for therapeutic use, namely, for the treatment of cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; cells for medical use; chemical, biochemical and biological preparations being biological, biochemical, and immunological pharmaceutical preparations for medical use | ACTIVE | — |
| 042 | Analysis and research in laboratories being research laboratory analysis services in the field of chemistry, biochemistry, and molecular biology; scientific research and analysis in the field of chemistry, biochemistry, molecular biology, and immunology; cell culture for scientific research purposes, for others; design and development of medical technologies; research and development in the field of biotechnology; research and development in the field of microorganisms and cells; research and development in the field of diagnostic preparations; pharmaceutical research and development; biochemical research and development; scientific and technological research, particularly in the biochemical, diagnostic or pharmaceutical fields; research and development for the pharmaceutical industry; research and development services in the field of proteins, microorganisms and cells; research and development services in the field of immunology; services of a chemical, biochemical and biological research laboratory; research services, namely, analyses in the field of molecular biology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by MabQuest SA
- Other trademarks owned by MabQuest SA
- Other trademarks owned by MabQuest SA
- Other trademarks owned by MabQuest Therapeutics SA
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named MABQUEST THERAPEUTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 10, 2026 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Aug 19, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 19, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 19, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 19, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 31, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 31, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 25, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 10, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 9, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 9, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 9, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 12, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 24, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 24, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 15, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 14, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 12, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 27, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 27, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 23, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |